Twist Bioscience

Twist Bioscience Liabilities

The The Liabilities of Twist Bioscience (TWST) as of Nov 5, 2026 is 168.90 M USD. In the previous year, The Liabilities was 141.63 M USD — a change of 19.25% (higher).

Liabilities

168.90 MUSD

YoY

19.25%

Last updated:

In 2025, Twist Bioscience's total liabilities amounted to 168.90 M USD, a 19.25% difference from the 141.63 M USD total liabilities in the previous year.

The Twist Bioscience Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
317.21 M USD
Jan 1, 2019
34.91 M USD
Jan 1, 2020
62.62 M USD
Jan 1, 2021
121.28 M USD
Jan 1, 2022
171.99 M USD
Jan 1, 2023
152.97 M USD
Jan 1, 2024
141.63 M USD
Jan 1, 2025
168.90 M USD
The Twist Bioscience Liabilities history
YEARLiabilitiesYoY
168.90 MUSD+19.25%
141.63 MUSD-7.41%
152.97 MUSD-11.06%
171.99 MUSD+41.82%
121.28 MUSD+93.67%
62.62 MUSD+79.37%
34.91 MUSD-88.99%
317.21 MUSD+44.84%
219.02 MUSD+43.08%
153.07 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Twist Bioscience Stock analysis

What does Twist Bioscience do? Twist Bioscience Corp is a company specializing in the production and applications of synthetic DNA. It was founded in 2013 and is based in San Francisco, California, USA. The company utilizes proprietary technologies to cost-effectively produce high-quality and high-quantity synthetic DNA. The company operates in three business areas: DNA synthesis, biopharmaceuticals, and data storage. The DNA synthesis division is the core of the company and involves the production of synthetic DNA for applications in various industries, including medicine, agricultural science, biotechnology, plastic engineering, and others. The company manufactures customized DNA synthesis products tailored to the needs of its customers, allowing them to accelerate and optimize their research and development projects. Twist Bioscience has also developed a proprietary technology called "Twist Biosensor" that enables rapid and cost-effective analysis of genetic variations. The biopharmaceutical division focuses on the development of therapeutics and diagnostics based on synthetic DNA. Twist Bioscience develops antibodies and proteins that can be used in cancer and immunotherapy, as well as diagnostics. In the data storage field, Twist Bioscience develops solutions for storing large amounts of data on DNA. This technology utilizes the dense and stable structure of DNA to securely and reliably store data in the long term. Twist Bioscience's DNA synthesis products are utilized by researchers, companies, and public institutions in various industries. Customers value not only the wide product portfolio but also the high quality and precision of the products, as well as the speed of order processing. The company operates a number of manufacturing facilities near its customers in Europe and Asia to ensure fast and efficient delivery of its products. This allows Twist Bioscience to have a strong position in the global market. In recent years, the company has achieved significant milestones. In 2018, Twist Bioscience went public and raised a total of $70 million through its IPO. The company has also established partnerships with various other companies and institutions to develop new applications and products. Overall, Twist Bioscience is a growing company specializing in the production and applications of synthetic DNA. With its wide range of high-quality and customized DNA synthesis products, as well as its innovative solutions in the biopharmaceutical and data storage sectors, the company has established a strong market position. Twist Bioscience is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Twist Bioscience's Liabilities

Twist Bioscience's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Twist Bioscience's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Twist Bioscience's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Twist Bioscience's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Twist Bioscience’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Twist Bioscience stock

The Liabilities of Twist Bioscience is 168.90 M USD in 2025.

The Liabilities of Twist Bioscience changed from 141.63 M USD to 168.90 M USD, representing a 19.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Twist Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Twist Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Twist Bioscience

All Key Metrics — Twist Bioscience